Seeks to amend Notification No.30/2013-Central Excise dated 29.11.2013 - 40/2015 - Central Excise - Tariff

Contents

[TO BE PUBLISHED IN THE GAZETTE OF INDIA, EXTRAORDINARY,

PART II, SECTION 3, SUB-SECTION (i)]

GOVERNMENT OF INDIA

MINISTRY OF FINANCE

(DEPARTMENT OF REVENUE)

Notification No. 40/2015-Central Excise

New Delhi, the 30th July, 2015

G.S.R. (E). - In exercise of the powers conferred by sub-section (1) of section 5A of the Central Excise Act, 1944 (1 of 1944), the Central Government being satisfied that it is necessary in the public interest so to do, hereby makes the following amendments in the notification of the Government of India in the Ministry of Finance (Department of Revenue), No.30/2013-Central Excise, dated the 29th November, 2013, published in the Gazette of India, Extraordinary, Part II, Section 3, Sub-section (i) vide number G.S.R. 763(E), dated the 29th November, 2013, namely: -

In the said notification,-

(a) in the Explanation, for the figures, letters and words “1st day of October, 2015” the figures, letters and words “1st day of April, 2016 ” shall be substituted;

(b) after the Explanation, for the TABLE, the following TABLE shall be substituted, namely:-

“TABLE

Sl. No.	Category	Description of goods
(1)	(2)	(3)
1.	Anti Tuberculosis Drugs	(i) New Cases (PC-1) (ii) Re-treatment cases (PC-2) (iii) Prolongation Pouches (PC-4) (iv) Pediatric Box (PC-13) (v) Pediatric Box (PC-14) (vi) Pediatric Pouch (PC-15) (vii) Pediatric Pouch (PC-16) (viii) Isoniazid-100 mg (PC-7) (ix) Ethambutol-800 mg (PC-10) (x) Isoniazid-300 mg (PC-11) (xi) Kanamycin 500 mg (PC-17) (xii) Kanamycin 1000 mg (PC-27) (xiii) Capreomycin 500 mg (PC-42) (xiv) Capreomycin 750 mg (PC-35) (xv) Capreomycin 1000 mg (PC-36) (xvi) Levoflox-250 mg (PC-28) (xvii) Levoflox-500 mg (PC-29) (xviii) Moxifloxacin 400 mg (PC-39) (xix) Cycloserine 250 mg (PC-24) (xx) Ethionamide 250 mg (PC-20) (xxi) Ethionamide 125 mg (PC-30) (xxii) Na-PAS 4 gm (PC-32) (xxiii) Na-PAS 10 gm (PC-25) (xxiv) Ethambulol 400 mg (PC-45) (xxv) Ethambulol 800 mg (PC-10) (xxvi) Pyrazinamide 500 mg (PC-8) (xxvii) Pyrazinamide 750 mg (PC-23) (xxviii) Pyridoxine 50 mg (PC-31) (xxix) Pyridoxine 100 mg (PC-26) (xxx) Clofazimine 100 mg (PC-40) (xxxi) Linezolid 600 mg (PC-38) (xxxii) Amoxyclav 875/125 mg (PC-43) (xxxiii) Sodium PAS 4 gm (PC-32) (xxxiv) Sodium PAS 10 gm (PC-25) (xxxv) Clarithromycin 500 mg (PC-37) (xxxvi) Thiacetazone 150 mg (PC-44) (xxxvii) Inj. Streptomycin-750mg (PC-5) (xxxviii) Cap Rifampicin-150mg(PC-6) (xxxix) Cap Rifabutin-150mg(PC-33)
2.	2. Diagnostics and Equipments	(i) Biosafety cabinet Class II A2 with UPS as per specification (ii) Bacteriologic Incubator (300 LT) (iii) Refrigerated centrifuge with UPS as per specification (iv) Autoclaves: Horizontal (v) Autoclaves: Vertical (vi) LPA Equipments (vii) LC Equipments (viii) LPA kits (ix) Liquid Culture reagents (x) Capillia Kits (xi) Fluorescence microscope (xii) DNA Sequencing kits (xiii) Inspissators (xiv) LED Fluorescence microscopes (xv) Binocular Microscopes (xvi) CB-NAAT machine (xvii) Cartridges (xviii) Annual Calibration.”.